LATEST
There are no tropical cyclones at this time.✦Android Auto’s unofficial video player now lets you play games in your car✦India Rejects Illegally Constituted Court of Arbitration's Indus Waters Treaty Award✦🔴 Football: French forward Bradley Barcola joins Liverpool from PSG in record-breaking Ligue 1 transfer✦How new broadcast technology is changing the way fans watch cricket✦
Mon, Aug 31, 2026
Loading weather...
Markets

Alnylam Presents New Data Validating AMVUTTRA In ATTR; Provides Updates On Zilebesiran

By Dhallo News · August 31, 2026 at 5:48 PM IST

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY), a RNAi therapeutics company, on Monday reported new data reinforcing the therapeutic ability of AMVUTTRA in treating transthyretin amyloidosis (ATTR). The data was presented at the European Society of Cardiology (ESC) Congress 2026

Original reporting: NasdaqRead original report →
Have feedback on this article?Report error or suggestion

Read More from Markets

Mitsui sees role as steward of scarce resources: CEO

Breaking News......

Read Article »

Stock Market prediction tomorrow, September 1: What will happen to Sensex, Nifty, Bank Nifty, KOSPI, Nikkei on Tuesday?

Asian equities closed lower on August 31 due to rising Middle East tensions and ...

Read Article »

Deepa Jewellers IPO: Price band, lot size, GMP, listing date and other key details of ₹460 crore issue

Deepa Jewellers' IPO opens on September 1, aiming to raise ₹459.72 crore throug...

Read Article »
Return to Front Page

Subscribe to Our Newsletter

Get the latest breaking news and top stories delivered straight to your inbox.